Brief: Baudax Bio Announces Clinical Program Update For Neuromuscular Blocking Agents
11/11/2021 12:05
Nov 11 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO ANNOUNCES CLINICAL PROGRAM UPDATE FOR
NEUROMUSCULAR
BLOCKING AGENTS BX-1000, BX-2000 AND BX-3000
* BAUDAX BIO INC - BX-2000 AND BX-3000 TO ADVANCE INTO
CLINICAL
STUDIES IN 2022
* BAUDAX BIO INC - BX-1000 COMPLETES DOSE-ESCALATION STUDY
* BAUDAX BIO INC - BX-1000 WAS GENERALLY WELL TOLERATED AND
RAPIDLY ACHIEVED MUSCLE PARALYSIS, ALONG WITH COMPLETE
SPONTANEOUS RECOVERY
Source text for Eikon: ID:nGNX5GJXNq
Further company coverage: BXRX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer